Treace Medical Concepts, Inc. (TMCI) Operating Margin
- Operating margin · 12 months: Value -26.17%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -26.17% | Operating income / revenue. Period ending 2026-06-30. $-53.72M ÷ $205.31M × 100 ≈ -26.17% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -53.72M USD | Operating Income (Loss) |
| Revenue | 205.31M USD | |
| Cost of products and services | 42.19M USD | Cost of Goods and Services Sold |
| Research and development | 18.22M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-53.72M | $205.31M | $42.19M | $18.22M | (m) | -26.17% |
| 2026-03-31 | $-55.74M | $207.32M | $42.05M | $19.34M | (m) | -26.89% |
| 2025-12-31 | $-54.15M | $212.69M | $42.94M | $20.28M | (m) | -25.46% |
| 2025-09-30 | $-48.44M | $218.88M | $44.05M | $20.95M | (m) | -22.13% |
| 2025-06-30 | $-47.89M | $213.75M | $42.50M | $21.23M | (m) | -22.41% |
| 2025-03-31 | $-52.30M | $210.82M | $41.64M | $20.89M | (m) | -24.81% |
| 2024-12-31 | $-55.69M | $209.36M | $41.09M | $20.59M | (m) | -26.60% |
| 2024-09-30 | $-62.27M | $202.86M | $39.33M | $19.53M | (m) | -30.69% |
| 2024-06-30 | $-64.95M | $198.53M | $38.38M | $18.92M | (m) | -32.71% |
| 2024-03-31 | $-56.62M | $196.03M | $37.27M | $17.29M | (m) | -28.88% |
| 2023-12-31 | $-51.43M | $187.12M | $35.18M | $15.44M | (m) | -27.48% |
| 2023-09-30 | $-48.14M | $174.68M | $34.72M | $15.04M | (m) | -27.56% |
| 2023-06-30 | $-41.64M | $166.97M | $32.82M | $14.49M | (m) | -24.94% |
| 2023-03-31 | $-40.52M | $154.99M | $30.43M | $13.94M | (m) | -26.15% |
| 2022-12-31 | $-34.84M | $141.84M | $27.52M | $13.58M | (m) | -24.57% |
| 2022-09-30 | $-36.94M | $125.51M | $24.09M | $13.21M | (m) | -29.44% |
| 2022-06-30 | $-31.09M | $114.07M | $21.71M | $11.95M | (m) | -27.25% |
| 2022-03-31 | $-23.20M | $104.76M | $20.00M | $11.39M | (m) | -22.15% |
| 2021-12-31 | $-16.51M | $94.42M | $17.83M | $10.20M | (m) | -17.49% |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | $855.00K | $57.37M | $12.47M | $5.85M | (m) | 1.49% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-3.54M | $39.42M | $7.63M | $5.07M | (m) | -8.97% |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mobia Medical, Inc. (MOBI) | United States | $0.293B | |
| TriSalus Life Sciences, Inc. (TLSI) | United States | $0.283B | -9.92 |
| Embecta Corp. (EMBC) | United States | $0.319B | 2.10 |
| Cytosorbents Corp (CTSO) | United States | $0.274B | -1.29 |
| ORASURE TECHNOLOGIES INC (OSUR) | United States | $0.272B | -6.26 |
| Anika Therapeutics, Inc. (ANIK) | United States | $0.272B | -51.71 |
| InfuSystem Holdings, Inc (INFU) | United States | $0.253B | 22.52 |
| UTAH MEDICAL PRODUCTS INC (UTMD) | United States | $0.238B | 20.93 |
| SHOULDER INNOVATIONS, INC. (SI) | United States | $0.355B | |
| Orchestra BioMed Holdings, Inc. (OBIO) | United States | $0.356B | -4.39 |